Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity

被引:7
作者
Wright, Phillip [1 ]
Kelsall, Janet [2 ]
Healing, Guy [2 ,3 ]
Sanderson, Julie [1 ]
机构
[1] Univ East Anglia, Sch Pharm, Norwich NR4 7TJ, Norfolk, England
[2] AstraZeneca, Alderley Pk, Macclesfield SK10 4TF, Cheshire, England
[3] Apconix Ltd, Biohub Alderley Pk, Macclesfield SK10 4TG, Cheshire, England
关键词
CDK; Human; Retina; Muller cell; Retinotoxicity; CDK inhibitors; CELL-CYCLE; DINACICLIB MK-7965; REGULATORY SUBUNIT; BIPOLAR CELLS; PHOSPHORYLATION; PROTEIN; CANCER; PHASE; FLAVOPIRIDOL; ACTIVATION;
D O I
10.1007/s00204-018-2376-8
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been associated with CDK inhibitors, including the pan-CDK inhibitor AG-012896. The purpose of this research was to use a novel planar sectioning technique to determine CDK expression profiles in the ex vivo human retina with the aim of identifying isoforms responsible for CDK retinotoxicity. Four CDK isoforms (CDK11, 16, 17 and 18) were selected as a result of IC50 data comparing neurotoxic (AG-012986 and NVP-1) and non-neurotoxic (dinaciclib and NVP-2) CDK inhibitors, with IC(50)s at CDK11 showing a clear difference between the neurotoxic and non-neurotoxic drugs. CDK11 was maximally expressed in the photoreceptor layer, whereas CDK16, 17 and 18 showed maximal expression in the inner nuclear layer. CDK5 (an isoform associated with retinal homeostasis) was maximally expressed in the retinal ganglion cell layer. Apart from CDK18, each isoform showed expression in the photoreceptor layer. The human Muller cell line MIO-M1 expressed CDK5, 11, 16 and 17 and AG-01298 (0.02-60 mu M) caused a dose-dependent increase in MIO-M1 cell death. In conclusion, CDK11 appears the most likely candidate for mediation of photoreceptor toxicity. RNA profiling can be used to determine the distribution of genes of interest in relation to retinal toxicity in the human retina.
引用
收藏
页码:659 / 671
页数:13
相关论文
共 50 条
  • [21] Extra-cell cycle regulatory functions of cyclin-dependent kinases (CDK) and CDK inhibitor proteins contribute to brain development and neurological disorders
    Kawauchi, Takeshi
    Shikanai, Mima
    Kosodo, Yoichi
    [J]. GENES TO CELLS, 2013, 18 (03) : 176 - 194
  • [22] Expression of the cyclin-dependent kinase inhibitor Dacapo is regulated by Cyclin E
    de Nooij, JC
    Graber, KH
    Hariharan, IK
    [J]. MECHANISMS OF DEVELOPMENT, 2000, 97 (1-2) : 73 - 83
  • [23] Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9
    Saqub, Hera
    Proetsch-Gugerbauer, Hannah
    Bezrookove, Vladimir
    Nosrati, Mehdi
    Vaquero, Edith M.
    de Semir, David
    Ice, Ryan J.
    McAllister, Sean
    Soroceanu, Liliana
    Kashani-Sabet, Mohammed
    Osorio, Robert
    Dar, Altaf A.
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [24] Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine
    DeAzevedo, WF
    Leclerc, S
    Meijer, L
    Havlicek, L
    Strnad, M
    Kim, SH
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2): : 518 - 526
  • [25] Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer
    Cress, W. Douglas
    Yu, Peng
    Wu, Jie
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2017, 91 : 98 - 101
  • [26] Novel small molecule cyclin-dependent kinases modulators in human clinical trials
    Senderowicz, AM
    [J]. CANCER BIOLOGY & THERAPY, 2003, 2 (04) : S84 - S95
  • [27] Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
    Squires, Matthew S.
    Feltell, Ruth E.
    Wallis, Nicola G.
    Lewis, E. Jonathan
    Smith, Donna-Michelle
    Cross, David M.
    Lyons, John F.
    Thompson, Neil T.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (02) : 324 - 332
  • [28] Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials
    Senderowicz, AM
    [J]. INVESTIGATIONAL NEW DRUGS, 1999, 17 (03) : 313 - 320
  • [29] Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials
    Adrian M. Senderowicz
    [J]. Investigational New Drugs, 1999, 17 : 313 - 320
  • [30] Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
    Meijer, L
    Borgne, A
    Mulner, O
    Chong, JPJ
    Blow, JJ
    Inagaki, N
    Inagaki, M
    Delcros, JG
    Moulinoux, JP
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2): : 527 - 536